We Need a Miracle: How Drug R&D Needs to Change to Cure Disease
Release Date: 09/12/2019
Make Me a Match! How AI Can Transform Clinical Trial Recruitment
underthedatascope's podcast
A majority of clinical trials fail because they can’t enroll enough patients. One reason for this is patients and clinical trials teams simply can’t find each other. Deep6 CEO Wout Brusselaers talks about how his company is using AI to transform the process of identifying patients for clinical trials and research, and how the challenges go way beyond just making the technology work.
info_outline
Bridging a Critical Gap: Using AI to Avoid Wasteful Treatments, Unnecessary Tests and Poor Outcomes
underthedatascope's podcast
ASCO's CancerLinq focused on a challenge of tremendous unmet need: Extracting, cleaning and codifying the data stored in dozens of electronic medical record systems in an attempt to understand how patients experience cancer care. Concerto HealthAI has been tasked with improving these care dynamics to help maximize the benefits of cancer treatments. CEO Jeff Elton speaks about how his company is building a world-class real-world data platform and tightly integrating it with AI-based tools and capabilities.
info_outline
We Need a Miracle: How Drug R&D Needs to Change to Cure Disease
underthedatascope's podcast
Healthcare digitization is booming and data-driven innovations are disrupting drug discovery. But we must learn how to use these emerging technologies better so that we can ask more sophisticated questions, and come up with deeper insights into biology and the understanding and treatment of disease. David Shaywitz talks about disruptive innovators and offers some sober views on how hard it is to re-invent drug R&D.
info_outline
Can You Read Me? How AI Can Help Bring Radiology Out of the Dark Ages
underthedatascope's podcast
The workload for radiologists has reached the point that it is impossible to keep up with demand. AI based technologies may be able to support new clinical workflows, improve automation, and ensure that physicians are focused on the cases that are most in need of their attention. Eyal Gura speaks on how he co-founded and built Zebra Medical Vision, one of the leading organizations poised to revolutionize radiology using AI.
info_outline
Who Owns Your Data? Agency, Autonomy, and Inclusivity in the Digital Age
underthedatascope's podcast
Precision medicine requires intimate knowledge of the patient in order to develop personalized treatments. But not all patients are willing to give their data to precision medicine companies. Sage Bionetworks CCO John Wilbanks explores data ownership and informed consent, as well as new ways of innovating with internet-based collaboration.
info_outline
Wedding Registries are a Thing of the Past; Genomic Registries are the Future
underthedatascope's podcast
The creation of population genomics registries can drive new disease insights and prove key in advancing early stage research. Wuxi NextCODE’s CMO Richard Williams talks about driving precision medicine research and how to handle, manage, and gain insights from the massive scale datasets.
info_outline
Trailer: Introducing Under the DataScope
underthedatascope's podcast
Under the DataScope is a six-episode podcast series from the Kraft Precision Medicine Accelerator at Harvard Business School, showcasing the most innovative companies bringing data & analytics technologies to precision medicine today. Guests include John Wilbanks of Sage Bionetworks, David Shaywitz of Takeda Ventures, Jeff Elton of Concerto Health AI, Wout Brusselaers, Founder & CEO of Deep6, Richard Williams of Wuxi NextCODE, and Eyal Gura, Founder & CEO, Zebra Medical Vision. Hosted by Gabriel Eichler.
info_outlineHealthcare digitization is booming and data-driven innovations are disrupting drug discovery. But we must learn how to use these emerging technologies better so that we can ask more sophisticated questions, and come up with deeper insights into biology and the understanding and treatment of disease. David Shaywitz talks about disruptive innovators and offers some sober views on how hard it is to re-invent drug R&D.